However, American, Canadian, and UK guidelines generally recommend using insulin as a third line treatment, therefore only after failing treatment on second line therapies [1–3, 18] unless the patient has symptoms of hyperglycemia or evidence of metabolic decompensation at the time of type 2 diabetes diagnosis [2, 19]. This evidence concerns the gene INS and Hyperglycemia.